Hormone Replacement Therapy: A Complete Guide for Men and Women

Hormone replacement therapy (HRT) is medical treatment that restores or supplements hormones — most commonly testosterone in men or estrogen (often with progesterone) in women — when the body's natural production has declined enough to cause diagnosed deficiency and associated symptoms. It is not a single protocol but a category of treatment that looks different for men and women, is guided by distinct clinical societies, and is always managed by a licensed physician based on bloodwork and clinical evaluation.

Hormones regulate far more than reproduction. Testosterone, estrogen, progesterone, and thyroid hormone influence energy, mood, sleep, bone density, muscle mass, cardiovascular health, and cognitive function in both sexes. When production of these hormones declines — through aging, menopause, illness, or other causes — the resulting symptoms can be broad and easy to misattribute to stress, poor sleep, or "just getting older." Hormone replacement therapy exists to address the underlying deficiency directly, once it has been properly diagnosed.

This article is a general orientation to hormone health for both men and women. It is not a substitute for a diagnostic workup or a prescribing relationship with a physician, and it does not describe specific doses, regimens, or schedules — those are clinical decisions made between a patient and their own licensed provider.

What hormone replacement therapy treats

In men, HRT most often refers to testosterone replacement therapy (TRT) for diagnosed hypogonadism — a condition in which the testes produce insufficient testosterone, causing symptoms such as low energy, reduced libido, mood changes, loss of muscle mass, or cognitive fog. The Endocrine Society's clinical practice guideline is explicit that a diagnosis should be made "only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations" — not from a single lab value or from symptoms alone. For a deeper look at how this specific therapy works, see our dedicated guide on testosterone replacement therapy and how TRT works.

In women, hormone therapy most often addresses the menopausal transition — perimenopause and menopause — when the ovaries reduce production of estrogen and progesterone. According to the National Institute on Aging, this decline "explain[s] the symptoms that some women experience during this time," which can include hot flashes, night sweats, vaginal dryness, sleep disruption, and mood changes, along with longer-term effects on bone density and metabolism. The Menopause Society (formerly NAMS) and the American College of Obstetricians and Gynecologists (ACOG) both maintain clinical guidance on menopausal hormone therapy, and both frame it as a treatment for specific, bothersome symptoms — not a blanket anti-aging intervention.

Thyroid hormone imbalances — hypothyroidism and hyperthyroidism — are a related but distinct category. They affect both sexes, share overlapping symptoms with sex-hormone deficiency (fatigue, weight change, mood disturbance), and are diagnosed and managed differently. A thorough hormone evaluation typically considers thyroid function alongside sex hormones rather than in isolation.

How diagnosis actually works

Across both men's and women's hormone therapy, the clinical pattern is the same: symptoms plus bloodwork, confirmed over more than one measurement, evaluated by a physician — never bloodwork alone, and never symptoms alone.

For men, the Endocrine Society guideline recommends measuring fasting morning total testosterone with a reliable assay as the initial test, then confirming a low result with a second measurement before diagnosing hypogonadism. This two-step confirmation exists because testosterone naturally fluctuates through the day and can be affected by illness, sleep, and stress — a single low draw is not sufficient grounds for a diagnosis.

For women, the diagnostic picture during perimenopause leans more heavily on symptoms and menstrual history than on a single hormone number, because estrogen and progesterone fluctuate considerably during the transition itself. Bloodwork (including FSH, LH, and estradiol) is still useful context, particularly to rule out other causes or to evaluate earlier-than-expected menopause, but ACOG and The Menopause Society both center clinical judgment and symptom burden in the decision to treat.

If you want a walkthrough of how to read the individual markers on a hormone panel — what each one measures and why reference ranges vary by lab — see our companion article on reading a hormone panel, and the site's marker-by-marker breakdown for deep dives on individual labs.

How the risk-benefit conversation differs by sex and age

One of the most important things to understand about hormone therapy is that the evidence base, and the resulting guidance, is not identical for men and women — and it isn't static across a person's lifespan either.

For women, The Menopause Society's 2022 position statement describes a "window of opportunity" concept: women who are younger than 60 or within about ten years of their final menstrual period generally have the most favorable benefit-risk profile for treating bothersome menopausal symptoms and preventing bone loss. For women who start hormone therapy more than ten years after menopause onset, or after age 60, the position statement notes the benefit-risk ratio is "less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia." This is precisely why timing, personal risk factors, and shared decision-making with a physician matter as much as the decision to treat at all.

For men, the Endocrine Society guideline takes a comparably cautious stance at the other end of the age spectrum: it recommends against routinely prescribing testosterone therapy to all men 65 and older simply because their testosterone is low, absent the symptom-plus-lab confirmation described above. The guideline also calls for ongoing monitoring — of symptoms, side effects, blood counts, and prostate-related markers — throughout treatment, not just at the point of diagnosis.

The throughline in both cases: hormone therapy is individualized medicine. It depends on age, symptom severity, personal and family health history, and ongoing monitoring — never a fixed recommendation that applies the same way to every patient.

Hormone replacement therapy is a clinical decision, made between a patient and their own licensed physician, based on confirmed lab values and a documented symptom picture — not a wellness product or a one-size-fits-all regimen.

Where peptides fit into the picture

Adjacent to traditional hormone replacement, some patients and physicians also discuss peptide therapies — short chains of amino acids that can influence the body's own hormone signaling pathways rather than replacing a hormone directly. Peptides are a distinct category from HRT with their own evidence base, use cases, and regulatory status. If you're curious how they relate, see our overviews of peptides and peptide classes explained.

Getting started the right way

If you suspect a hormone imbalance — whether it's low testosterone, perimenopausal symptoms, or something less specific like persistent fatigue or mood change — the responsible starting point is the same regardless of sex: a conversation with a licensed physician and a proper diagnostic panel, not a guess based on symptoms alone or a protocol borrowed from someone else's treatment plan. Reference ranges, confirmatory testing, and ongoing monitoring exist because hormone levels are dynamic and individual, and because treatment carries real risks alongside real benefits that only a clinician can weigh against your specific history.

This article is educational and does not constitute medical advice, a diagnosis, or a prescription. Adonis TRT Club does not sell or dispense hormones or controlled substances; all treatment decisions are made by your own licensed physician.